Japan Grants Conditional, Time-Limited Approval to Two iPSC Therapies

Japan’s Ministry of Health, Labour and Welfare granted conditional, time-limited marketing approval to two iPS cell-derived regenerative medicine products, RiHEART and AMCHEPRY, on 6 March 2026. The decisions mark a significant step in translating iPS cell research into therapeutic applications. [1]

Two products, different clinical purposes

RiHEART, developed by Cuorips, uses iPS cell-derived cardiomyocytes for transplantation in ischemic cardiomyopathy. Its development builds on research led by Professor Yoshiki Sawa at the University of Osaka. [1]

AMCHEPRY, developed by Sumitomo Pharma, uses iPS cell-derived dopaminergic neural progenitor cells. It is indicated for improving motor symptoms in Parkinson’s disease patients whose response to existing drug treatments, including levodopa-containing products, is inadequate. The approval followed an investigator-initiated clinical study at Kyoto University Hospital. [2]

Approval with further evaluation

Japan’s conditional, time-limited pathway requires safety confirmation and a reasonable prediction of efficacy. It also requires further evaluation after marketing and a subsequent application for full approval within the designated period. [1]

Sumitomo Pharma’s approval announcement states that it will conduct a post-marketing clinical study and surveillance for AMCHEPRY to support full approval. [2] This makes evidence collection after the initial decision a central part of the development pathway, not simply an administrative follow-up.

For the regenerative medicine sector, the next stage is therefore as important as the approval milestone: establishing how treatment outcomes and safety develop over time in the intended patient population. The questions are product-specific, including which outcomes are measured and how consistently they are observed.

The two approvals should not be interpreted as evidence of a cure or as validation of iPS cell-based treatments generally. Different cells, manufacturing methods and clinical applications require their own evidence. The significance of March 2026 lies in these defined therapeutic programmes advancing under a regulatory framework that retains requirements for further assessment.